140 related articles for article (PubMed ID: 35729536)
41. Prognostic value of the 6-gene OncoMasTR test in hormone receptor-positive HER2-negative early-stage breast cancer: Comparative analysis with standard clinicopathological factors.
Lynch SM; Russell NM; Barron S; Wang CA; Loughman T; Dynoodt P; Fender B; Lopez-Ruiz C; O'Grady A; Sheehan KM; Fay J; Amberger-Murphy V; Saha A; Klinger R; Gonzalez CA; Al-Attar N; Rahman A; O'Leary D; Lanigan FT; Bracken AP; Crown J; Kelly CM; O'Connor DP; Gallagher WM
Eur J Cancer; 2021 Jul; 152():78-89. PubMed ID: 34090143
[TBL] [Abstract][Full Text] [Related]
42. Establishment and validation of a novel autophagy-related gene signature for patients with breast cancer.
Du JX; Chen C; Luo YH; Cai JL; Cai CZ; Xu J; Ni XJ; Zhu W
Gene; 2020 Dec; 762():144974. PubMed ID: 32707305
[TBL] [Abstract][Full Text] [Related]
43. Classification of breast cancer patients using somatic mutation profiles and machine learning approaches.
Vural S; Wang X; Guda C
BMC Syst Biol; 2016 Aug; 10 Suppl 3(Suppl 3):62. PubMed ID: 27587275
[TBL] [Abstract][Full Text] [Related]
44. Integrating germline and somatic variation information using genomic data for the discovery of biomarkers in prostate cancer.
Mamidi TKK; Wu J; Hicks C
BMC Cancer; 2019 Mar; 19(1):229. PubMed ID: 30871495
[TBL] [Abstract][Full Text] [Related]
45. Iatrogenic endometriosis harbors somatic cancer-driver mutations.
Lac V; Verhoef L; Aguirre-Hernandez R; Nazeran TM; Tessier-Cloutier B; Praetorius T; Orr NL; Noga H; Lum A; Khattra J; Prentice LM; Co D; Köbel M; Mijatovic V; Lee AF; Pasternak J; Bleeker MC; Krämer B; Brucker SY; Kommoss F; Kommoss S; Horlings HM; Yong PJ; Huntsman DG; Anglesio MS
Hum Reprod; 2019 Jan; 34(1):69-78. PubMed ID: 30428062
[TBL] [Abstract][Full Text] [Related]
46. Integrating mutation and gene expression cross-sectional data to infer cancer progression.
Fleck JL; Pavel AB; Cassandras CG
BMC Syst Biol; 2016 Jan; 10():12. PubMed ID: 26810975
[TBL] [Abstract][Full Text] [Related]
47. Association between histone lysine methyltransferase KMT2C mutation and clinicopathological factors in breast cancer.
Chen X; Zhang G; Chen B; Wang Y; Guo L; Cao L; Ren C; Wen L; Liao N
Biomed Pharmacother; 2019 Aug; 116():108997. PubMed ID: 31146111
[TBL] [Abstract][Full Text] [Related]
48. Prognostic value of the 21-gene recurrence score in ER-positive, HER2-negative, node-positive breast cancer was similar in node-negative diseases: a single-center study of 800 patients.
Wu J; Gao W; Chen X; Fei C; Lin L; Chen W; Huang O; Zhu S; He J; Li Y; Zhu L; Shen K
Front Med; 2021 Aug; 15(4):621-628. PubMed ID: 33367943
[TBL] [Abstract][Full Text] [Related]
49. Somatic mutation and gain of copy number of PIK3CA in human breast cancer.
Wu G; Xing M; Mambo E; Huang X; Liu J; Guo Z; Chatterjee A; Goldenberg D; Gollin SM; Sukumar S; Trink B; Sidransky D
Breast Cancer Res; 2005; 7(5):R609-16. PubMed ID: 16168105
[TBL] [Abstract][Full Text] [Related]
50. Integrated analysis of tumor mutation burden and immune infiltrates in endometrial cancer.
Zhou H; Chen L; Lei Y; Li T; Li H; Cheng X
Curr Probl Cancer; 2021 Apr; 45(2):100660. PubMed ID: 33012523
[TBL] [Abstract][Full Text] [Related]
51. Somatic mutation profiling and associations with prognosis and trastuzumab benefit in early breast cancer.
Loi S; Michiels S; Lambrechts D; Fumagalli D; Claes B; Kellokumpu-Lehtinen PL; Bono P; Kataja V; Piccart MJ; Joensuu H; Sotiriou C
J Natl Cancer Inst; 2013 Jul; 105(13):960-7. PubMed ID: 23739063
[TBL] [Abstract][Full Text] [Related]
52. Epigenomic and Transcriptomic Characterization of Secondary Breast Cancers.
Graff-Baker AN; Orozco JIJ; Marzese DM; Salomon MP; Hoon DSB; Goldfarb M
Ann Surg Oncol; 2018 Oct; 25(10):3082-3087. PubMed ID: 29956094
[TBL] [Abstract][Full Text] [Related]
53. Characterization of AKT Somatic Mutations in Chinese Breast Cancer Patients.
Wen L; Zhang G; Ren C; Li X; Mok H; Jia M; Wang Y; Chen B; Li K; Cao L; Li C; Xiao W; Lai J; Lin J; Wei G; Li Y; Zhang Y; Chen X; Liao N
Cancer Manag Res; 2021; 13():3055-3065. PubMed ID: 33854375
[TBL] [Abstract][Full Text] [Related]
54. Co-mutation of TP53 and PIK3CA in residual disease after neoadjuvant chemotherapy is associated with poor survival in breast cancer.
Chen X; Guo Y; Ouyang T; Li J; Wang T; Fan Z; Fan T; Lin B; Xu Y; Xie Y
J Cancer Res Clin Oncol; 2019 May; 145(5):1235-1242. PubMed ID: 30806788
[TBL] [Abstract][Full Text] [Related]
55. TP53 mutation is an independent prognostic marker for poor outcome in both node-negative and node-positive breast cancer.
Overgaard J; Yilmaz M; Guldberg P; Hansen LL; Alsner J
Acta Oncol; 2000; 39(3):327-33. PubMed ID: 10987229
[TBL] [Abstract][Full Text] [Related]
56. Increased RNA Expression of von Willebrand Factor Gene Is Associated With Infiltrating Lobular Breast Cancer and Normal PAM50 Subtype.
Lehrer S; Green S; Dembitzer FR; Rheinstein PH; Rosenzweig KE
Cancer Genomics Proteomics; 2019; 16(3):147-153. PubMed ID: 31018945
[TBL] [Abstract][Full Text] [Related]
57. TP53 mutations determined by targeted NGS in breast cancer: a case-control study.
Andrikopoulou A; Terpos E; Chatzinikolaou S; Apostolidou K; Ntanasis-Stathopoulos I; Gavriatopoulou M; Dimopoulos MA; Zagouri F
Oncotarget; 2021 Oct; 12(21):2206-2214. PubMed ID: 34676052
[TBL] [Abstract][Full Text] [Related]
58. The clinicomolecular landscape of de novo versus relapsed stage IV metastatic breast cancer.
Seltzer S; Corrigan M; O'Reilly S
Exp Mol Pathol; 2020 Jun; 114():104404. PubMed ID: 32067942
[TBL] [Abstract][Full Text] [Related]
59. The prevalence of estrogen receptor-1 mutation in advanced breast cancer: The estrogen receptor one study (EROS1).
Najim O; Huizing M; Papadimitriou K; Trinh XB; Pauwels P; Goethals S; Zwaenepoel K; Peterson K; Weyler J; Altintas S; van Dam P; Tjalma W
Cancer Treat Res Commun; 2019; 19():100123. PubMed ID: 30826563
[TBL] [Abstract][Full Text] [Related]
60. Gene Expression Signatures of BRCAness and Tumor Inflammation Define Subgroups of Early-Stage Hormone Receptor-Positive Breast Cancer Patients.
Schroth W; Büttner FA; Kandabarau S; Hoppe R; Fritz P; Kumbrink J; Kirchner T; Brauer HA; Ren Y; Henderson D; Madden SF; Sauer G; Fehm T; Wallwiener D; Fasching PA; Mürdter T; Schwab M; Brauch H;
Clin Cancer Res; 2020 Dec; 26(24):6523-6534. PubMed ID: 33008814
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
